Definitive Healthcare (NASDAQ:DH) Issues FY 2026 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 0.160-0.19 for the period, compared to the consensus EPS estimate of 0.140. The company issued revenue guidance of $220.0 million-$226.0 million, compared to the consensus revenue estimate of $223.5 million. Definitive Healthcare also updated its Q2 2026 guidance to 0.030-0.040 EPS.

Definitive Healthcare Price Performance

NASDAQ:DH traded down $0.02 during trading hours on Thursday, reaching $0.92. The stock had a trading volume of 331,909 shares, compared to its average volume of 354,274. The stock has a market capitalization of $97.23 million, a PE ratio of -0.74, a PEG ratio of 84.12 and a beta of 1.34. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.64 and a current ratio of 1.64. The company has a 50 day moving average price of $1.10 and a two-hundred day moving average price of $1.99. Definitive Healthcare has a 52 week low of $0.90 and a 52 week high of $4.70.

Definitive Healthcare (NASDAQ:DH) last released its earnings results on Thursday, May 7th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.03. The firm had revenue of $55.93 million for the quarter, compared to the consensus estimate of $55.02 million. Definitive Healthcare had a positive return on equity of 2.63% and a negative net margin of 57.52%.Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. As a group, sell-side analysts anticipate that Definitive Healthcare will post 0.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

DH has been the topic of several analyst reports. Barclays cut their target price on Definitive Healthcare from $2.75 to $1.00 and set an “underweight” rating on the stock in a research report on Monday, March 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Definitive Healthcare in a research report on Wednesday, January 21st. Canaccord Genuity Group cut their target price on Definitive Healthcare from $4.00 to $3.00 and set a “hold” rating on the stock in a research report on Friday, February 27th. Zacks Research raised Definitive Healthcare from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. Finally, Wall Street Zen raised Definitive Healthcare from a “hold” rating to a “buy” rating in a research report on Saturday, March 14th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, five have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $3.27.

Hedge Funds Weigh In On Definitive Healthcare

Hedge funds have recently bought and sold shares of the business. Raymond James Financial Inc. bought a new position in Definitive Healthcare in the 2nd quarter valued at $32,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Definitive Healthcare during the 4th quarter worth $35,000. HRT Financial LP bought a new position in shares of Definitive Healthcare during the 4th quarter worth $47,000. ExodusPoint Capital Management LP bought a new position in shares of Definitive Healthcare during the 4th quarter worth $47,000. Finally, Bayesian Capital Management LP bought a new position in shares of Definitive Healthcare during the 2nd quarter worth $55,000. Institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.